SequelSEC

Fortress Biotech, Inc. FBIO

Pharmaceutical Preparations · CIK 0001429260 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$68.47M
Fiscal year ended 2026-06-30
Operating income
-$29.34M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$43.74MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / net income6.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue0.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin10.8%84th
Long-term debt / equity0.88x75th
Current ratio2.49x35th
SBC / revenue45.4%61th
Gross margin66.9%41th
Operating margin-111.0%57th
Revenue YoY growth9.7%57th

Fortress Biotech, Inc. (FBIO) reported revenue of $68.47M and net income of $111.82M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Fortress Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Fortress Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$68.47M
Cost of revenue$23.56M
Gross profit$44.91M
Operating income-$29.34M
Net income$111.82M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$145.86M
Income tax expense$4.66M
Diluted EPSUnavailable
Selling, general & administrative$68.84M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Fortress Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$196.58M
Total assets$316.72M
Current assets$245.51M
Total liabilities$110.63M
Current liabilities$62.02M
Total equity incl. NCI$206.09M
Temporary (mezzanine) equityUnavailable
Inventory$8.16M
Accounts receivable$36.25M
GoodwillUnavailable
Long-term debt$35.00M
Accounts payable$11.86M

Cash flow

Fortress Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$125.92M
Capital expendituresUnavailable
Investing cash flow$2.79M
Financing cash flow-$6.52M
Net change in cash$122.19M
Stock-based compensation$10.29M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Fortress Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin65.6%
Operating margin-42.9%
FCF marginUnavailable
SBC / revenue15.0%
Current ratio3.96x
Revenue YoY growth20.5%
Net margin163.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equity0.17x
Effective tax rate3.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.